lenalidomide,idecabtagene vicleucel
Bms,2Seventy Bio
['bet', 'ide-cel', 'fil,veral,12', 'karmma', 'karmma-2']
congress l #ash22 - ide-cel achieves deep responses in patients with mm who relapse after frontline after asct. with crs and nt similar to patients receiving ide-cel in later lines, the clinical benefit-risk profile in favourable early line 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma